Page last updated: 2024-11-04

diaminopimelic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Diaminopimelic Acid: A diamino derivative of heptanedioic acid with amino groups at C-2 and C-6 and the general formula (COOH)CH(NH2)CH2CH2CH2CH(NH2)(COOH). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

LL-2,6-diaminopimelic acid : A 2,6-diaminopimelic acid in which both chiral centres have S configuration. It is a component of bacterial cell wall. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439283
CHEBI ID16026
SCHEMBL ID15987065
MeSH IDM0006205

Synonyms (73)

Synonym
(s-(r*,r*))-2,6-diaminoheptanedioic acid
l,l-2,6-diaminopimelic acid
(s,s)-2,6-diaminopimelic acid
CHEBI:16026
(2s,6s)-2,6-diaminoheptanedioic acid
diaminopimelic acid
l,l-diaminopimelic acid
ll-a2pm
l-2,6-diaminopimelic acid
l-threo-2,6-diaminopimelic acid
heptanedioic acid, 2,6-diamino-, (2s,6s)-
heptanedioic acid, 2,6-diamino-, [s-(r*,r*)]- (9ci)
heptanedioic acid, 2,6-diamino-, (s-(r*,r*))-
meso-alpha,epsilon-diaminopimelic acid
l,l-alpha,epsilon-diaminopimelic acid
heptanedioic acid, 2,6-diamino-, (2s,6s)- (8ci)
meso-alpha,alpha'-diaminopimelic acid
l-diaminopimelic acid
(s,s)-diaminopimelate
l-diaminopimelate
l-alpha,epsilon-diaminopimelic acid
14289-34-0
C00666
meso-1-alpha,epsilon-diaminopimelate
d,l-meso-diaminoheptanedioate
ll-2,6-diaminoheptanedioate
ll-2,6-diaminopimelate
d,l-diaminopimelate
LL-DIAMINOPIMELATE ,
l,l-2,6-diaminopimelate
ll-2,6-diaminopimelic acid
DB03590
diamino-pimelic acid
2,6-diamino-heptanedioic acid
LMFA01170102
unii-k3i8an6s7f
k3i8an6s7f ,
AKOS006328540
(6s,2s)-diaminopimelic acid
SCHEMBL15987065
heptanedioic acid,2,6-diamino-, (2s,6s)-
dl-2,6-diaminopimelic acid, >=95% (tlc)
a,e-diaminopimelate
2,6-diamino-heptanedioate
(2r,6s)-2,6-diamino-heptanedioic acid
meso-2,6-diaminoheptanedioic acid
meso-alpha,epsilon-diaminopimelate
2,6-diaminopimelate
a,a'-diaminopimelate
( (r*,s*)-2,6-diamino-heptanedioic acid
meso-2,6-diamino-heptanedioic acid
dl-2,6-diaminoheptanedioate
ll-2,6-diaminoheptanedioic acid
a,e-diaminopimelic acid
(2r,6s)-2,6-diamino-heptanedioate
meso-alpha,alpha'-diaminopimelate
dl-2,6-diaminopimelate
l,l-2,6-diaminoheptanedioic acid
meso-2,6-diamino-heptanedioate
dl-2,6-diaminopimelic acid
(r*,s*)-2,6-diamino-heptanedioate
( (r*,s*)-2,6-diamino-heptanedioate
d,l-meso-diaminoheptanedioic acid
(r*,s*)-2,6-diamino-heptanedioic acid
a,a'-diaminopimelic acid
(2s,6s)-2,6-diaminoheptanedioicacid
Q27094515
diaminopimelic acid, (6s,2s)-
(2s,6s)-2,6-diamino-heptanedioic acid
diaminopimelic acid, dl-2,6-
DTXSID701313562
CS-0446200
PD006789

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Finally, dapB gene expression showed a gene dosage effect which suggests that it is not controlled by an element present in limiting amounts in the cell."( Nucleotide sequence and expression of the Escherichia coli dapB gene.
Bouvier, J; Patte, JC; Richaud, C; Richaud, F; Stragier, P, 1984
)
0.27
" The killing ability of macrophages and polymorphonuclear leukocytes of the immunosuppressed mice was also markedly enhanced by dosing with FK-156."( Immunoactive peptides, FK-156 and FK-565. II. Restoration of host resistance to microbial infection in immunosuppressed mice.
Goto, S; Kuwahara, S; Mine, Y; Nishida, M; Wakai, Y; Watanabe, Y; Yokota, Y, 1983
)
0.27
" When FK-565 and related compounds were encapsulated in multilamellar (MLV) liposomes composed of phosphatidylcholine and phosphatidylserine, dose-response experiments showed that they were about 800 times more effective than the free compounds in activating AM."( Activation by a new synthetic acyltripeptide and its analogs entrapped in liposomes of rat alveolar macrophages to the tumor cytotoxic state.
Mutsuura, S; Ogawara, M; Sone, S; Tsubura, E; Utsugi, T, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
2,6-diaminopimelic acidThe amino dicarboxylic acid that is heptanedioic acid with amino substituents at C-2 and C-6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Peptidoglycan cytoplasmic synthesis and recycling pathways834
superpathway of lysine, threonine and methionine biosynthesis II032
superpathway of lysine, threonine and methionine biosynthesis I038
lysine biosynthesis VI019
lysine biosynthesis I024
Lysine biosynthesis I224
Lysine biosynthesis II226
Lysine biosynthesis VI319

Research

Studies (1,593)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990297 (18.64)18.7374
1990's100 (6.28)18.2507
2000's168 (10.55)29.6817
2010's886 (55.62)24.3611
2020's142 (8.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews20 (1.24%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1,591 (98.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]